Edgewise Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Edgewise Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $187.10M.
- Edgewise Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $238.80M.
- Edgewise Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $129.16M.
- Edgewise Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $186.15M.
- Edgewise Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $187.10M, a 21.65% decline from fiscal 2024.
- Edgewise Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $238.80M, a 354.42% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $52.55M, a 59.32% decline from fiscal 2022.
- Edgewise Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $129.16M, a 30.61% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $187.10M 10-K · filed 2026-02-26 | |
| 2025-06-30 | $187.10M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $238.80M 10-K · filed 2026-02-26 | |
| 2024-03-31 | $238.80M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $52.55M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $129.16M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $129.16M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $186.15M 10-K · filed 2023-02-23 | |
| 2021-03-31 | $186.15M 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |